Bern, February 10, 2026

Space Peptides Pioneers Fully Fluorine-Free Peptide Manufacturing, Setting New Standard in Sustainable Pharmaceutical Production

Space Peptides, a leader in advanced peptide synthesis, today announced the successful development and implementation of an end-to-end fluorine-free peptide manufacturing platform. This breakthrough technology eliminates all fluorine-containing reagents—including hazardous PFAS compounds—from solid-phase peptide synthesis (SPPS), cleavage, and purification processes, positioning the company at the forefront of the green chemistry movement and regulatory compliance in the EU and globally.

Driven by Regulation, Built on Sustainability

With the European Union’s stringent Regulation (EU) 2025/718 drastically reducing PFAS thresholds—such as a 99.75% reduction in PFOS limits—the demand for fluorine-free alternatives has become mandatory for market access. Space Peptides’ innovative process directly addresses this urgent regulatory and environmental, health, and safety (EHS) challenge, transforming compliance into a competitive advantage.

A Complete Fluorine-Free Process

Space Peptides’ proprietary platform ensures no use of fluorine-based chemicals at any stage:

• Synthesis: No HBTU, HATU, HFIP, or fluoride salts. Efficient coupling is achieved under mild temperature conditions (≤30°C).
• Cleavage: Replaces toxic trifluoroacetic acid (TFA) and other fluorinated solvents with safer alternatives like methanesulfonic acid (MSA) and formic acid.
• Purification: Utilizes TFA-free solvent systems, ensuring final product purity without environmental or operator hazard.

Proven Performance and Scalability

The technology delivers superior results without compromising quality or efficiency:

• Ultra-High Purity: Chemical purity consistently exceeds 99.5%, with critical impurities controlled below 0.1%.
• Cost & Yield Advantages: Overall synthetic yield surpasses 90% while simultaneously reducing production costs compared to conventional fluorinated processes.
• Industrial Scalability: Ready for kilogram to metric-ton scale production under full cGMP compliance, meeting USP/EP standards.

Case Study: Sustainable Octreotide Production

A recent synthesis of the therapeutic peptide Octreotide demonstrated the system’s effectiveness. Using an entirely fluorine-free protection strategy and mild, ambient-temperature conditions, the process achieved high-purity cyclized peptide without TFA, HFIP, or fluoride salts—showcasing a viable, scalable pathway for complex peptide manufacturing.

Strategic Market Position

As the EU peptide market is projected to reach USD 12 billion in 2025, Space Peptides is uniquely positioned to capture growth in pharmaceuticals, cosmetics, and medical aesthetics. By mastering core fluorine-free technologies, the company not only meets stringent regulations but also aligns with growing consumer and industry demand for environmentally safe products.

About Space Peptides

Space Peptides, a Peptide CRDMO headquartered in Bern/Switzerland with global manufacturing assets is specialized in the research, development, and manufacturing of high-purity peptides using sustainable and compliant chemical processes. Committed to innovation and environmental stewardship, the company enables partners to achieve regulatory readiness and market leadership through green chemistry solutions.